Drug development for neglected diseases

Field test for various open innovation initiatives

Authors

DOI:

https://doi.org/10.14512/tatup.26.1-2.37

Keywords:

neglected diseases, research and development, market failure, open innovation

Abstract

There is a lack of sufficient research and development regarding diseases almost exclusively affection poor countries. One reason is seen in the financially weak demand, which can not sufficiently stimulate the complex commercialized product development. In recent years, national and international measures have been discussed and partly been implemented to attenuate the systemic problem of the patent-based innovation process, at least for poverty-related diseases. Some Stakeholders are testing how the idea of open source software development – the collaboration of volunteers generate products that are not owned by a company – can be transferred to drug development. They open different elements of the pharmacological innovation process for sharing and further drug development. Partly they call this Open Innovation. The article presents relevant initiatives.

References

Bianchi, Mattia; Cavaliere, Alberto; Chiaroni, Davide; Frattini, Frederico; Chiesa, Vittorio (2011): Organisational Modes for Open Innovation in the Bio-Pharmaceutical Industry: An Exploratory Analysis. In: Technovation 31 (1), S. 22–33. DOI: https://doi.org/10.1016/j.technovation.2010.03.002

Boseley, Sarah (2010): How GlaxoSmithKline Chief has Changed the Agenda for Big Pharma. Online verfügbar unter https://www.theguardian.com/business/2010/jan/20/glaxosmithkline-andrew-witty-drugs-developing-world, zuletzt geprüft am 01. 06. 2017.

Chesbrough, Henry William (2003): Open Innovation: The New Imperative for Creating and Profiting from Technology. Boston: Harvard Business School Press.

Chesbrough, Henry William; Bogers, Marcel (2014): Explicating Open Inovation: Clarifying an Emerging Paradigm for Understanding Innovation. In: Henry William Chesbrough, Wim Vanhaverbeke, Joel West (Hg.): New Frontiers in Open Innovation. Oxford: Oxford University Press, S. 3–28. DOI: https://doi.org/10.1093/acprof:oso/9780199682461.003.0001

CIPIH – Commission on Intellectual Property Rights, Innovation and Public Health (2006): Public Health – Innovation and Intellectual Property Rights. Online verfügbar unter http://www.who.int/intellectualproperty/documents/thereport/ENPublicHealthReport.pdf?ua=, zuletzt geprüft am 01. 06. 2017.

CMH – Commission on Macroeconomics and Health (2001): Macroeconomics and Health: Investing in Health for Economic Development. Genf: World Health Organization.

DNDi – Drugs for Neglected Diseases initiative (2011): Striving for Increasingly Open Innovation Models. Online verfügbar unter https://www.dndi.org/wp-content/uploads/2011/11/Striving_for_increasingly_open_innovation_models.pdf, zuletzt geprüft am 01. 06. 2017.

Eppinger, Elisabeth (2014): Patentpools. Eigenschaften, Motive und Implikationen. Wiesbaden: Springer Gabler. DOI: https://doi.org/10.1007/978-3-658-10109-1

Guth, Robert A. (2010): Glaxo Tries a Linux Approach. Drug Maker Shares its Research Data Online in Test of Open-Source Principles. In: The Wall Street Journal vom 26. 03. 2010.

MalariaGEN (2008): Joint Policy on Data Sharing, Intellectual Property and Publications. Online verfügbar unter https://www.malariagen.net/sites/default/files/content/project/files/JointPolicy-DataSharing-IntellectualProperty-Publications.pdf, zuletzt geprüft am 01. 06. 2017.

Moldenhauer, Oliver; Frisch, Philipp; Gombe-Götz, Spring (2012): „From Bench to Bedside“: Innovations- und Produktionsprozesse von Medizintools – alternative Konzepte zur Förderung von kommerzieller und nichtkommerzieller FuE, die einen breiten Zugang zu Innovationen sicherstellen. Gutachten im Auftrag des Deutschen Bundestags. Berlin: unveröffentlichtes Manuskript.

Moran, Mary et al. (2017): G-Finder 2015. Neglected Disease Research and Development: The Ebola Effect. Online verfügbar unter http://www.policycures.org/downloads/Y8%20GFINDER%20full%20report%20web.pdf, zuletzt geprüft am 01. 06. 2017.

TAB – Büro für Technikfolgen-Abschätzung beim Deutschen Bundestag (2017): Neue Arzneimittel gegen vernachlässigte Krankheiten. TAB-Arbeitsbericht Nr. 170, Autorin: Katrin Gerlinger, Berlin: TAB.

WHA – World Health Assembly (2008): Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property. Online verfügbar unter http://apps.who.int/gb/ebwha/pdf_files/WHA61-REC1/A61_REC1-en.pdf, zuletzt geprüft am 01. 06. 2017.

WHO – World Health Organisation (2015): Investing to Overcome the Global Impact of Neglected Tropical Diseases. Third WHO Report on Neglected Tropical Diseases. Online verfügbar unter http://apps.who.int/iris/bitstream/10665/152781/1/9789241564861_eng.pdf, zuletzt geprüft am 01. 01. 2017.

Published

15.08.2017

How to Cite

1.
Gerlinger K. Drug development for neglected diseases: Field test for various open innovation initiatives. TATuP [Internet]. 2017 Aug. 15 [cited 2024 Mar. 29];26(1-2):37-42. Available from: https://www.tatup.de/index.php/tatup/article/view/24